MM-120 is an LSD treatment in development for patients suffering from anxiety disorders. The latest trial data today is for its use in treating patients with Generalized Anxiety Disorder (GAD).
Results from an ongoing Phase II clinical trial of MM-120 were published in peer-reviewed scientific journal Biological Psychiatry. The data expands on what was presented at the PSYCH Symposium event earlier this year.
The Phase II clinical trial has MindMed giving patients a single dose of MM-120 to treat anxiety symptoms. The primary endpoint is seeing the effects of this single dose four weeks after administration. Secondary endpoints include effects after 12 weeks, as well as safety and tolerability.
Rob Barrow, CEO and Director of MindMed, said the following in a news release:
‘This paper further reinforces the positive preliminary evidence for LSD in patients who suffer from anxiety disorders. Acute administration of LSD produced long-lasting and notable reductions of anxiety and comorbid depression symptoms for up to 16 weeks.”
MNMD is seeing decent trading with more than 600,000 shares on the move as of this writing. That’s quickly approaching the company’s daily average trading volume of about 773,000 shares.
MNMD stock is up 2.3% as of Thursday morning but down about 62% since the start of the year.
There’s more recent stock market news worth checking out below!
We’ve got all the latest stock news traders need to know about for Thursday! That includes what has shares of Asana (NYSE:ASAN), QuickLogic (NASDAQ:QUIK) and Apple (NASDAQ:AAPL) stock on the move. You can find all of this news at the following links!
More Thursday Stock Market News
- CEO Dustin Moskovitz Just Doubled Down on Asana (ASAN) Stock
- QUIK Stock Gains 10% as QuickLogic Receives $7 Million Contract
- AAPL Stock Alert: 13 Takeaways From the Latest Apple Event 2022
On the date of publication, William White did not hold (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com Publishing Guidelines.